Evidence Summary
Evidence Level: Preliminary
Mechanism: Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
GLP-1/GIP agonist early Long COVID trials (metabolic/anti-inflammatory). Weekly titrated injection. GI side effects, cost. May benefit overweight subsets. Very early.